Market revenue in 2023 | USD 1,849.4 million |
Market revenue in 2030 | USD 5,805.3 million |
Growth rate | 17.8% (CAGR from 2023 to 2030) |
Largest segment | Functional genomics |
Fastest growing segment | Pathway Analysis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Functional Genomics, Epigenomics, Pathway Analysis, Biomarker Discovery |
Key market players worldwide | Agilent Technologies Inc, Bio-Rad Laboratories Inc, Danaher Corp, Eppendorf, Eurofins Scientific SE, Roche Holding AG ADR, GE Aerospace, Illumina Inc, Myriad Genetics Inc, Oxford Nanopore Technologies PLC, Pacific Biosciences of California Inc, Qiagen NV, Quest Diagnostics Inc, Thermo Fisher Scientific Inc, 23andMe Holding Co Class A |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to genomics market will help companies and investors design strategic landscapes.
Functional genomics was the largest segment with a revenue share of 32.39% in 2023. Horizon Databook has segmented the Japan genomics market based on functional genomics, epigenomics, pathway analysis, biomarker discovery covering the revenue growth of each sub-segment from 2018 to 2030.
Healthcare and clinical research service providers in Japan have been integrating sequencing technologies for the past couple of years and are expected to account for a considerable share of Asia Pacific genomics revenue share.
Ongoing developments in HLA and prenatal NGS testing coupled with international collaborations with American & European companies are expected to fuel the growth of Japan genomics market during the forecast period. Moreover, many hospitals in Japan have started using NGS-based mutational profile screening for patients with solid tumors to direct patients to relevant clinical trials.
Various cancer gene panels that are to be used in clinical practice have also been approved by the Ministry of Health, Labour and Welfare of Japan. However, a medical protocol for reporting and interpreting clinical variants must be developed. Using sequencing technology in this field, significant progress has been made in understanding the molecular causes of cancer.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan genomics market , including forecasts for subscribers. This country databook contains high-level insights into Japan genomics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account